Ahmad Hatim Sulaiman

2 papers in the library · 288 citations · publishing 2020-2022

Papers

Sort Most recent Most cited

Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.

Clinical Psychopharmacology and Neuroscience February 28, 2022 Hong Jin Jeon, Po-Chung Ju, Ahmad Hatim Sulaiman et al.

To evaluate the long-term safety and efficacy of intranasal esketamine in patients with treatment-resistant depression from the Asian subgroup of the SUSTAIN-2 study. SUSTAIN-2 was a phase 3, open-label, single-arm, multicenter study comprising a 4-week screening, 4-week induction, 48-week optimization/maintenance, and 4-week follow-up (upon esketamine discontinuation) phase. Patients with...

DOI: 10.9758/cpn.2022.20.1.70 Full text Depressive disorder Esketamine Administration Antidepressive agents +3

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression

The Journal of Clinical Psychiatry April 20, 2020 Ewa Wajs, Leah Aluisio, Richard Holder et al. 288 citations

OBJECTIVE: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). METHODS: This phase 3, open-label, multicenter, long-term (up to 1 year) study was conducted between October 2015 and October 2017. Patients (≥ 18 years) with TRD (DSM-5 diagnosis of major depressive disorder and nonresponse...

DOI: 10.4088/jcp.19m12891